IRONWOOD PHARMACEUTICALS, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $151.80 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2019-02-25
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $151.80M.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2016 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2018-12-31 | $151.80M 10-K · filed 2019-02-25 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $0.00 10-K · filed 2018-02-22 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-02 | ||
| 2016-12-31 | $0.00 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |